1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US

BACKGROUND: As of March 2023, two pneumococcal conjugate vaccines, 13- (PCV13) and 15- (PCV15) valent formulations, are recommended for US infants under a 3+1 schedule. PCV20 was approved by the FDA in June of 2021 for adults ≥18 years and most recently in April 2023 for children < 18 years. This...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenbaum, Mark, Huang, Liping, Perdrizet, Johnna, Cane, Alejandro D, Arguedas, Adriano, Hayford, Kyla, Tort, Maria J, Chapman, Ruth, Snow, Vincenza, Chilson, Erica, Farkouh, Ray, Dillon-Murphy, Desmond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677968/
http://dx.doi.org/10.1093/ofid/ofad500.1569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677968/
http://dx.doi.org/10.1093/ofid/ofad500.1569

Ejemplares similares